Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: A meta-analytic review

Pharmacogenomics

Volumn 15, Issue 7, 2014, Pages 963-976

  Cargnin, Sarah ^a   Jommi, Claudio ^a   Canonico, Pier Luigi ^a   Genazzani, Armando A ^a   Terrazzino, Salvatore ^a  

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

57:01; abacavir hypersensitivity; clinical utility; diagnostic accuracy; HLA B; meta analysis

Indexed keywords

ABACAVIR; HLA B57 ANTIGEN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HLA B ANTIGEN; HLA-B*57:01 ANTIGEN;

COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DRUG HYPERSENSITIVITY; GENETIC SCREENING; HEALTH CARE COST; HLA B57 GENE; HUMAN; IMMUNE RESPONSE; META ANALYSIS; PROGNOSIS; REVIEW; RISK REDUCTION; SENSITIVITY AND SPECIFICITY; SYSTEMATIC REVIEW; GENETICS; HIV INFECTIONS; PATHOLOGY; PHARMACOGENETICS;

ANTI-HIV AGENTS; DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; GENETIC TESTING; HIV INFECTIONS; HLA-B ANTIGENS; HUMANS; PHARMACOGENETICS;

EID: 84903161723     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.14.52     Document Type: Review

References (53)

1. Foster RH, Faulds D. Abacavir. Drugs 55(5), 729-736 (1998).
2. Hervey PS, Perry M. Abacavir: a review of its clinical potential in patients with HIV infection. Drugs 60(2), 447-479 (2000).
3. Chaponda M, Pirmohamed M. Hypersensitivity reactions to HIV therapy. Br. J. Clin. Pharmacol. 71(5), 659-671 (2011).
4. Hetherington S, McGuirk S, Powell G et al. Hypersensitivity reactions during therapy with the nucleoside reverse transcriptase inhibitor abacavir. Clin. Ther. 23(10), 1603-1614 (2001).
5. Clay PG. The abacavir hypersensitivity reaction: a review. Clin. Ther. 24(10), 1502-1514 (2002).
6. Chung WH, Hung SI, Chen YT. Human leukocyte antigens and drug hypersensitivity. Curr. Opin. Allergy Clin. Immunol. 7(4), 317-323 (2007).
7. Phillips EJ, Mallal SA. Pharmacogenetics of drug hypersensitivity. Pharmacogenomics 11(7), 973-987 (2010).
8. Pavlos R, Mallal S, Phillips E. HLA and pharmacogenetics of drug hypersensitivity. Pharmacogenomics 13(11), 1285-1306 (2012).
9. Mallal S, Nolan D, Witt C et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359(9308), 727-732 (2002).
10. Hetherington S, Hughes AR, Mosteller M et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359(9312), 1121-1122 (2002).
11. Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*57:01 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101(12), 4180-4185 (2004).
12. Rauch A, Nolan D, Martin A, McKinnon E, Almeida C, Mallal S. Prospective genetic screening decreases the incidence of abacavir hypersensitivity reactions in the Western Australian HIV cohort study. Clin. Infect. Dis. 43(1), 99-102 (2006).
13. Saag M, Balu R, Phillips E et al. Study of Hypersensitivity to Abacavir and Pharmacogenetic Evaluation Study Team. High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients. Clin. Infect. Dis. 46(7), 1111-1118 (2008).
14. Mallal S, Phillips E, Carosi G et al. PREDICT-1 Study Team. HLA-B*57:01 screening for hypersensitivity to abacavir. N. Engl. J. Med. 358(6), 568-579 (2008).
15. Gatsonis C, Paliwal P. Meta-analysis of diagnostic and screening test accuracy evaluations: methodologic primer. AJR Am. J. Roentgenol. 187(2), 271-281 (2006).
16. Whiting PF, Rutjes AW, Westwood ME et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann. Intern. Med. 155(8), 529-536 (2011).
17. QUADAS-2 (Quality Assessment of Diagnostic Accuracy Studies-2) tool. www.bris.ac.uk/quadas
18. Hughes AR, Mosteller M, Bansal AT et al. Association of genetic variations in HLA-B region with hypersensitivity to abacavir in some, but not all, populations. Pharmacogenomics 5(2), 203-211 (2004).
19. Bowonwatanuwong C, Warren L, Mosteller M et al. Association of HLA-B*5701 and hypersensitivity to abacavir in a sample of Thai patients. Presented at: 7th International Workshop on Adverse Drug Reactions and Lipodystrophyin HIV. Dublin, Ireland, 13-16 November 2005.
20. Reeves I, Churchill D, Fisher M. Screening for HLA-B*5701 reduces the frequency of abacavir hypersenitivity reactions. Presented at: 8th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. CA, USA, 24-26 September 2006.
21. Stekler J, Maenza J, Stevens C et al. Abacavir hypersensitivity reaction in primary HIV infection. AIDS 20(9), 1269-1274 (2006).
22. Rodríguez-Nóvoa S, García-Gascó P, Blanco F et al. Value of the HLA-B*57:01 allele to predict abacavir hypersensitivity in Spaniards. AIDS Res. Hum. Retroviruses 23(11), 1374-1376 (2007).
23. Phillips E, Rauch A, Nolan D et al. Genetic characterization of patients with MHC class I mediated abacavir hypersensitivity reaction. Presented at: 4th International AIDS Society meeting. Sydney, Australia, 23-25 July 2007.
24. Waters LJ, Mandalia S, Gazzard B, Nelson M. Prospective HLA-B*57:01 screening and abacavir hypersensitivity: a single centre experience. AIDS 21(18), 2533-2534 (2007).
25. Zucman D, Truchis Pd, Majerholc C, Stegman S, Caillat-Zucman S. Prospective screening for human leukocyte antigen-B*5701 avoids abacavir hypersensitivity reaction in the ethnically mixed French HIV population. J. Acquir. Immune Defic. Syndr. 45(1), 1-3 (2007).
26. Khan F, Gill J, Berka N. Strong association of HLA-B*57:01 with abacavir hypersensitivity among HIV-1 positive patients: a potential pharmacogenetic predictive test. Presented at: 34th Annual Meeting of the American-Societyfor-Histocompatibility-and-Immunogenetics. Toronto, Canada, 27-31 October 2008.
27. Rauch A, Nolan D, Thurnheer C et al. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study. Antivir. Ther. 13(8), 1019-1028 (2008).
28. Giorgini S, Martinelli C, Tognetti L et al. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients. Dermatol. Ther. 24(6), 591-594 (2011).
29. Berka N, Gill JM, Liacini A, O'Bryan T, Khan FM. Human leukocyte antigen (HLA) and pharmacogenetics: screening for HLA-B*57:01 among human immunodeficiency viruspositive patients from southern Alberta. Hum. Immunol. 73(2), 164-167 (2012).
30. Lijmer JG, Bossuyt PM, Heisterkamp SH. Exploring sources of heterogeneity in systematic reviews of diagnostic tests. Stat. Med. 21(11), 1525-1537 (2002).
31. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control. Clin. Trials 7(3), 177-188 (1986).
32. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat. Med. 21(11), 1539-1558 (2002).
33. Moses LE, Shapiro D, Littenberg B. Combining independent studies of a diagnostic test into a summary ROC curve: dataanalytic approaches and some additional considerations. Stat. Med. 12(14), 1293-1316 (1993).
34. Zamora J, Abraira V, Muriel A, Khan K, Coomarasamy A. Meta-DiSc: a software for meta-analysis of test accuracy data. BMC Med. Res. Methodol. 6, 31 (2006).
35. Meta-DiSc software version 1.4. www.hrc.es/investigacion/metadisc-en.htm
36. Open Meta-Analyst. http://tuftscaes.org/open-meta
37. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109), 629-634 (1997).
38. Nieves Calatrava D, Calle-Martín Ode L, Iribarren-Loyarte JA et al. Cost-effectiveness analysis of HLA-B*57:01 typing in the prevention of hypersensitivity to abacavir in HIV+ patients in Spain. Enferm. Infecc. Microbiol. Clin. 28(9), 590-595 (2010).
39. Kauf TL, Farkouh RA, Earnshaw SR, Watson ME, Maroudas P, Chambers MG. Economic efficiency of genetic screening to inform the use of abacavir sulfate in the treatment of HIV. Pharmacoeconomics 28(11), 1025-1039 (2010).
40. Somkrua R, Eickman EE, Saokaew S, Lohitnavy M, Chaiyakunapruk N. Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. BMC Med. Genet. 12, 118 (2011).
41. Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin. Pharmacol. Ther. 92(6), 757-765 (2012).
42. Cheung YK, Cheng SH, Chan EJ, Lo SV, Ng MH, Kwan P. HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese. Epilepsia 54(7), 1307-1314 (2013).
43. Tangamornsuksan W, Chaiyakunapruk N, Somkrua R, Lohitnavy M, Tassaneeyakul W. Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 149(9), 1025-1032 (2013).
44. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics 14(6), 335-342 (2004).
45. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The cost-effectiveness of HLA-B*57:01 genetic screening to guide initial antiretroviral therapy for HIV. AIDS 22(15), 2025-2033 (2008).
46. Guo Y, Shi L, Hong H, Su Z, Fuscoe J, Ning B. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci. China Life Sci. 56(2), 119-124 (2013)
47. Saito S, Ota S, Yamada E, Inoko H, Ota M. Allele frequencies and haplotypic associations defined by allelic DNA typing at HLA class I and class II loci in the Japanese population. Tissue Antigens 56(6), 522-529 (2000).
48. Munderi P, Snowden WB, Walker AS et al. Distribution of HLA-B alleles in a Ugandan HIV-infected adult population: NORA pharmacogenetic substudy of DART. Trop. Med. Int. Health 16(2), 200-204 (2011).
49. Martin MA, Kroetz DL. Abacavir pharmacogenetics-from initial reports to standard of care. Pharmacotherapy 33(7), 765-775 (2013).
50. Gazzard BG, Anderson J, Babiker A et al. British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008. HIV Med. 9(8), 563-608 (2008).
51. Aberg JA, Kaplan JE, Libman H et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin. Infect. Dis. 49(5), 651-681 (2009).
52. Antinori A, Marcotullio S, Ammassari A et al. Italian guidelines for the use of antiretroviral agents and the diagnostic-clinical management of HIV-1 infected persons. Update 2011. New Microbiol. 35(2), 113-159 (2012).
53. Lalonde RG, Thomas R, Rachlis A et al. Successful implementation of a national HLA-B*57:01 genetic testing service in Canada. Tissue Antigens 75(1), 12-18 (2010).